Patents by Inventor Stefan Somlo

Stefan Somlo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250082663
    Abstract: The present invention provides methods for treating or preventing Autosomal Dominant Polycystic Kidney Disease (ADPKD) and/or Autosomal Dominant Polycystic Liver Disease (ADPLD) and/or Autosomal Recessive Polycystic Kidney Disease (ARPKD) in a mammal.
    Type: Application
    Filed: June 14, 2022
    Publication date: March 13, 2025
    Inventors: Matteus KRAPPITZ, Sorin FEDELES, Stefan SOMLO
  • Publication number: 20180362574
    Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.
    Type: Application
    Filed: April 13, 2018
    Publication date: December 20, 2018
    Applicants: Massachusetts Institute of Technology, Yale University
    Inventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
  • Patent number: 9982009
    Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 29, 2018
    Assignees: Massachusetts Institute of Technology, Yale University
    Inventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
  • Publication number: 20150105361
    Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Applicants: Massachusetts Institute of Technology, Yale University
    Inventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
  • Publication number: 20080188449
    Abstract: In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD 1 and/or PKD2, is mutated; calcium signaling is abnormal; or both, such as polycystic kidney disease.
    Type: Application
    Filed: November 15, 2005
    Publication date: August 7, 2008
    Applicant: Yale University
    Inventors: Craig M. Crews, Stephanie J. Quinn, Stefan Somlo, Dayne Okuhara
  • Publication number: 20080063601
    Abstract: Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2 agonists, particularly agonists (calcium channel agonists) that target PC-2 directly and/or selectively, are administered to individuals with mutations in PKD1, in order to alter the course of polycystic kidney disease, particularly ADPKD. In specific embodiments, the invention relates to use of PC-2 agonists triptolide and triptolide derivatives to regulate calcium release. In other aspects, the invention relates to use of PC-2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD1 and/or PKD2, is mutated; calcium signaling is abnormal; or both.
    Type: Application
    Filed: March 12, 2007
    Publication date: March 13, 2008
    Applicant: Yale University
    Inventors: Stefan Somlo, Craig Crews, Stephanie Quinn, Dayne Okuhara
  • Publication number: 20080057506
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Application
    Filed: June 26, 2007
    Publication date: March 6, 2008
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Patent number: 7294465
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: November 13, 2007
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Patent number: 7083915
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: August 1, 2006
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Publication number: 20050170399
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Application
    Filed: January 21, 2005
    Publication date: August 4, 2005
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Publication number: 20020061520
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Application
    Filed: January 2, 2001
    Publication date: May 23, 2002
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Patent number: 6228591
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: May 8, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stefan Somlo, Toshio Mochizuki
  • Patent number: 6031088
    Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: February 29, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stefan Somlo, Toshio Mochizuki